대한뉴팜

054670KOSDAQ의약품 제조업

50.0 / 100

Reference Date: 2026-06-10

Financial Score23.5 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 13.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DaeHan New Pharm operates in various sectors including specialty pharmaceuticals, non-essential pharmaceuticals (obesity & wellness injectables), and animal pharmaceuticals, focusing on chronic disease treatments and expanding into new areas such as dementia and Parkinson's. The company is diversifying its business through animal pharmaceuticals and biotech, leveraging stem cell-based anti-aging and cell therapies. Sales are structured as a multi-product, small-volume model, and the company manages foreign exchange risks through asset-liability matching strategies.

Number of Employees

393people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

5.23Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR

0.58Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

11.50Industry Average 4.017.0Point

2.9x industry avg (excellent)

Debt Ratio

41.35Industry Average 12.430.0Point

3.3x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼19.0% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 12.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 5,680Won52-week high 8,38052-week low 5,630

1-month return1.0Point

1m -13.28% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
Neutral주식등의대량보유상황보고서(일반)2026-05-29
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-26
Neutral주식등의대량보유상황보고서(일반)2026-05-19
Neutral분기보고서 (2026.03)2026-05-13